Literature DB >> 26920989

Acute Fibrinolysis Shutdown after Injury Occurs Frequently and Increases Mortality: A Multicenter Evaluation of 2,540 Severely Injured Patients.

Hunter B Moore1, Ernest E Moore2, Ioannis N Liras3, Eduardo Gonzalez2, John A Harvin3, John B Holcomb3, Angela Sauaia2, Bryan A Cotton3.   

Abstract

BACKGROUND: Fibrinolysis is a physiologic process that maintains microvascular patency by breaking down excessive fibrin clot. Hyperfibrinolysis is associated with a doubling of mortality. Fibrinolysis shutdown, an acute impairment of fibrinolysis, has been recognized as a risk factor for increased mortality. The purpose of this study was to assess the incidence and outcomes of fibrinolysis phenotypes in 2 urban trauma centers. STUDY
DESIGN: Injured patients included in the analysis were admitted between 2010 and 2013, were 18 years of age or older, and had an Injury Severity Score (ISS) > 15. Admission fibrinolysis phenotypes were determined by the clot lysis at 30 minutes (LY30): shutdown ≤ 0.8%, physiologic 0.9% to 2.9%, and hyperfibrinolysis ≥ 3%. Logistic regression was used to adjust for age, arrival blood pressure, ISS, mechanism, and facility.
RESULTS: There were 2,540 patients who met inclusion criteria. Median age was 39 years (interquartile range [IQR] 26 to 55 years) and median ISS was 25 (IQR 20 to 33), with a mortality rate of 21%. Fibrinolysis shutdown was the most common phenotype (46%) followed by physiologic (36%) and hyperfibrinolysis (18%). Hyperfibrinolysis was associated with the highest death rate (34%), followed by shutdown (22%), and physiologic (14%, p < 0.001). The risk of mortality remained increased for hyperfibrinolysis (odds ratio [OR] 3.3, 95% CI 2.4 to 4.6, p < 0.0001) and shutdown (OR 1.6, 95% CI 1.3 to 2.1, p = 0.0003) compared with physiologic when adjusting for age, ISS, mechanism, head injury, and blood pressure (area under the receiver operating characteristics curve 0.82, 95% CI 0.80 to 0.84).
CONCLUSIONS: Fibrinolysis shutdown is the most common phenotype on admission and is associated with increased mortality. These data provide additional evidence of distinct phenotypes of coagulation impairment and that individualized hemostatic therapy may be required.
Copyright © 2016 American College of Surgeons. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2016        PMID: 26920989      PMCID: PMC4834914          DOI: 10.1016/j.jamcollsurg.2016.01.006

Source DB:  PubMed          Journal:  J Am Coll Surg        ISSN: 1072-7515            Impact factor:   6.113


  47 in total

1.  Fibrinolysis.

Authors:  G R Fearnley
Journal:  Ann R Coll Surg Engl       Date:  1967-07       Impact factor: 1.891

2.  The significance of coagulative and thrombotic changes after haemorrhage and injury.

Authors:  R M Hardaway
Journal:  J Clin Pathol Suppl (R Coll Pathol)       Date:  1970

3.  Complexing of tissue plasminogen activator with PAI-1, alpha 2-macroglobulin, and C1-inhibitor: studies in patients with defibrination and a fibrinolytic state after electroshock or complicated labor.

Authors:  B Bennett; A Croll; K Ferguson; N A Booth
Journal:  Blood       Date:  1990-02-01       Impact factor: 22.113

Review 4.  Seven haemostatic gene polymorphisms in coronary disease: meta-analysis of 66,155 cases and 91,307 controls.

Authors:  Zheng Ye; Eugene H C Liu; Julian P T Higgins; Bernard D Keavney; Gordon D O Lowe; Rory Collins; John Danesh
Journal:  Lancet       Date:  2006-02-25       Impact factor: 79.321

5.  Hypercoagulability is most prevalent early after injury and in female patients.

Authors:  Martin A Schreiber; Jerome Differding; Per Thorborg; John C Mayberry; Richard J Mullins
Journal:  J Trauma       Date:  2005-03

6.  Plasminogen activator inhibitor (PAI-1) in plasma and platelets.

Authors:  N A Booth; A J Simpson; A Croll; B Bennett; I R MacGregor
Journal:  Br J Haematol       Date:  1988-11       Impact factor: 6.998

7.  Acute traumatic coagulopathy.

Authors:  Karim Brohi; Jasmin Singh; Mischa Heron; Timothy Coats
Journal:  J Trauma       Date:  2003-06

8.  Acute coagulopathy of trauma: hypoperfusion induces systemic anticoagulation and hyperfibrinolysis.

Authors:  Karim Brohi; Mitchell J Cohen; Michael T Ganter; Marcus J Schultz; Marcel Levi; Robert C Mackersie; Jean-François Pittet
Journal:  J Trauma       Date:  2008-05

9.  Measurement of plasminogen activator inhibitor 1 in biologic fluids with a murine monoclonal antibody-based enzyme-linked immunosorbent assay.

Authors:  P J Declerck; M C Alessi; M Verstreken; E K Kruithof; I Juhan-Vague; D Collen
Journal:  Blood       Date:  1988-01       Impact factor: 22.113

10.  PLASMA RESUSCITATION PROMOTES COAGULATION HOMEOSTASIS FOLLOWING SHOCK-INDUCED HYPERCOAGULABILITY.

Authors:  Jessica C Cardenas; Andrew P Cap; Michael D Swartz; Maria Del Pilar Huby; Lisa A Baer; Nena Matijevic; Bryan A Cotton; John B Holcomb; Charles E Wade
Journal:  Shock       Date:  2016-02       Impact factor: 3.454

View more
  73 in total

1.  Obesity is associated with postinjury hypercoagulability.

Authors:  Jason M Samuels; Ernest E Moore; Julia R Coleman; Joshua J Sumislawski; Mitchell J Cohen; Christopher C Silliman; Anirban Banerjee; Arsen Ghasabyan; James Chandler; Angela Sauaia
Journal:  J Trauma Acute Care Surg       Date:  2019-10       Impact factor: 3.313

Review 2.  Damage Control Resuscitation.

Authors:  Jason M Samuels; Hunter B Moore; Ernest E Moore
Journal:  Chirurgia (Bucur)       Date:  2017 Sept-Oct

3.  [Uncritical use of tranexamic acid in trauma patients : Do no further harm!]

Authors:  M Maegele
Journal:  Unfallchirurg       Date:  2016-11       Impact factor: 1.000

Review 4.  Fibrinolysis Shutdown in Trauma: Historical Review and Clinical Implications.

Authors:  Hunter B Moore; Ernest E Moore; Matthew D Neal; Forest R Sheppard; Lucy Z Kornblith; Dominik F Draxler; Mark Walsh; Robert L Medcalf; Mitch J Cohen; Bryan A Cotton; Scott G Thomas; Christine M Leeper; Barbara A Gaines; Angela Sauaia
Journal:  Anesth Analg       Date:  2019-09       Impact factor: 5.108

5.  Redefining postinjury fibrinolysis phenotypes using two viscoelastic assays.

Authors:  Gregory R Stettler; Ernest E Moore; Hunter B Moore; Geoffrey R Nunns; Christopher C Silliman; Anirban Banerjee; Angela Sauaia
Journal:  J Trauma Acute Care Surg       Date:  2019-04       Impact factor: 3.313

6.  Does Tranexamic Acid Improve Clot Strength in Severely Injured Patients Who Have Elevated Fibrin Degradation Products and Low Fibrinolytic Activity, Measured by Thrombelastography?

Authors:  Hunter B Moore; Ernest E Moore; Michael P Chapman; Kirk C Hansen; Mitchell J Cohen; Frederic M Pieracci; James Chandler; Angela Sauaia
Journal:  J Am Coll Surg       Date:  2019-03-29       Impact factor: 6.113

7.  The role of NIGMS P50 sponsored team science in our understanding of multiple organ failure.

Authors:  Frederick A Moore; Ernest E Moore; Timothy R Billiar; Yoram Vodovotz; Anirban Banerjee; Lyle L Moldawer
Journal:  J Trauma Acute Care Surg       Date:  2017-09       Impact factor: 3.313

8.  Tranexamic acid is associated with increased mortality in patients with physiological fibrinolysis.

Authors:  Hunter B Moore; Ernest E Moore; Benjamin R Huebner; Gregory R Stettler; Geoffrey R Nunns; Peter M Einersen; Christopher C Silliman; Angela Sauaia
Journal:  J Surg Res       Date:  2017-05-08       Impact factor: 2.192

9.  The hyperfibrinolytic phenotype is the most lethal and resource intense presentation of fibrinolysis in massive transfusion patients.

Authors:  John R Taylor; Erin E Fox; John B Holcomb; Sandro Rizoli; Kenji Inaba; Martin A Schreiber; Karen Brasel; Thomas M Scalea; Charles E Wade; Eileen Bulger; Bryan A Cotton
Journal:  J Trauma Acute Care Surg       Date:  2018-01       Impact factor: 3.313

10.  Systemic hyperfibrinolysis after trauma: a pilot study of targeted proteomic analysis of superposed mechanisms in patient plasma.

Authors:  Anirban Banerjee; Christopher C Silliman; Ernest E Moore; Monika Dzieciatkowska; Marguerite Kelher; Angela Sauaia; Kenneth Jones; Michael P Chapman; Eduardo Gonzalez; Hunter B Moore; Angelo D'Alessandro; Erik Peltz; Benjamin E Huebner; Peter Einerson; James Chandler; Arsen Ghasabayan; Kirk Hansen
Journal:  J Trauma Acute Care Surg       Date:  2018-06       Impact factor: 3.313

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.